Changes in Serum Irisin in Response to Metformin Treatment in Iraqi Women Patients with Polycystic Ovary Syndrome

Abstract

Background: Polycystic ovary syndrome (PCOS) is the most prevalent endocrine condition in women, characterized by hyperandrogenism. Infrequent ovulation and multiple follicular cysts in hypertrophied sized ovaries, hyperinsulinemia and insulin resistance irisin a myokine play a vital role in the pathogenesis of many diseases characterized by insulin resistance. Objective: Assessment of the effect of metformin on the level of serum irisin in PCOS women compared to non– metformin-treated PCOS patients and healthy controls. Material and methods: This analytical cross-sectional included 88 females whose ages ranged from (18-to 40) years. All females were selected from the infertility treatment and IVF center of Kamal Al-Samarraey Hospital Baghdad/ Iraq from October 2020 to March 2021. Women were divided into three groups: group (a) involved 33 women with polycystic ovary syndrome metformin treatment, group (b) involved 37 women with polycystic ovary don't receive metformin group (c) involved (23) healthy women (act as controls). Each Serum specimen was analyzed to measure irisin, fasting insulin, fasting glucose, and homeostasis model assessment of insulin resistance (HOMA-IR). Results: significantly higher serum levels of irisin, fasting insulin and HOMA-IR were found in both groups of polycystic ovary women compared to healthy women. There was no significant difference in serum irisin levels between the two groups of polycystic ovary syndrome. Conclusion: It has been concluded that serum irisin levels did not change in response to metformin treatment.